Monopar Therapeutics (MNPR) stock
MNPRNasdaqPharmaceutical PreparationsFiscal year ends December 31
$71.06−0.91 (-1.26%)
Close on Nov 17, 2026Market cap $476.97MP/E –Yield –
Monopar Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Monopar Therapeutics's total assets was $134.98M at Jun 30, 2026. For fiscal 2025 it was $140.72M, up 133.4% from the year before. The highest annual figure on record is $140.72M in fiscal 2025.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $140.72M | +133.4% |
| FY2024 | Dec 31, 2024 | $60.29M | +720.8% |
| FY2023 | Dec 31, 2023 | $7.35M | -44.5% |
| FY2022 | Dec 31, 2022 | $13.23M | -35.5% |
| FY2021 | Dec 31, 2021 | $20.52M | +21.7% |
| FY2020 | Dec 31, 2020 | $16.87M | +26.3% |
| FY2019 | Dec 31, 2019 | $13.35M | +82.5% |
| FY2018 | Dec 31, 2018 | $7.32M | -26.3% |
| FY2017 | Dec 31, 2017 | $9.93M | +243.0% |
| FY2016 | Dec 31, 2016 | $2.90M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $134.98M | +150.6% |
| Q1 FY2026 | Mar 31, 2026 | $137.98M | +150.5% |
| Q4 FY2025 | Dec 31, 2025 | $140.72M | +133.4% |
| Q3 FY2025 | Sep 30, 2025 | $144.20M | +2275.7% |
| Q2 FY2025 | Jun 30, 2025 | $53.87M | +650.2% |
| Q1 FY2025 | Mar 31, 2025 | $55.09M | +518.1% |
| Q4 FY2024 | Dec 31, 2024 | $60.29M | +720.8% |
| Q3 FY2024 | Sep 30, 2024 | $6.07M | -29.4% |
| Q2 FY2024 | Jun 30, 2024 | $7.18M | -30.6% |
| Q1 FY2024 | Mar 31, 2024 | $8.91M | -24.7% |
| Q4 FY2023 | Dec 31, 2023 | $7.35M | -44.5% |
| Q3 FY2023 | Sep 30, 2023 | $8.59M | -40.5% |
| Q2 FY2023 | Jun 30, 2023 | $10.34M | -38.2% |
| Q1 FY2023 | Mar 31, 2023 | $11.83M | -34.5% |
| Q4 FY2022 | Dec 31, 2022 | $13.23M | -35.5% |
| Q3 FY2022 | Sep 30, 2022 | $14.45M | -35.8% |
| Q2 FY2022 | Jun 30, 2022 | $16.74M | -31.6% |
| Q1 FY2022 | Mar 31, 2022 | $18.07M | -30.3% |
| Q4 FY2021 | Dec 31, 2021 | $20.52M | +21.7% |
| Q3 FY2021 | Sep 30, 2021 | $22.52M | +24.0% |
| Q2 FY2021 | Jun 30, 2021 | $24.46M | +91.0% |
| Q1 FY2021 | Mar 31, 2021 | $25.91M | +101.8% |
| Q4 FY2020 | Dec 31, 2020 | $16.87M | +26.3% |
| Q3 FY2020 | Sep 30, 2020 | $18.16M | +255.4% |
| Q2 FY2020 | Jun 30, 2020 | $12.80M | +128.8% |
| Q1 FY2020 | Mar 31, 2020 | $12.84M | +102.1% |
| Q4 FY2019 | Dec 31, 2019 | $13.35M | +82.5% |
| Q3 FY2019 | Sep 30, 2019 | $5.11M | -35.2% |
| Q2 FY2019 | Jun 30, 2019 | $5.60M | -33.8% |
| Q1 FY2019 | Mar 31, 2019 | $6.35M | -30.5% |
| Q4 FY2018 | Dec 31, 2018 | $7.32M | -26.3% |
| Q3 FY2018 | Sep 30, 2018 | $7.89M | +172.4% |
| Q2 FY2018 | Jun 30, 2018 | $8.45M | – |
| Q1 FY2018 | Mar 31, 2018 | $9.15M | – |
| Q4 FY2017 | Dec 31, 2017 | $9.93M | – |
| Q4 FY2016 | Dec 31, 2016 | $2.90M | – |
See a number that looks wrong?